[1] Adam R, Vinet E. Regional treatment of metastasis:surgery of colorectal liver metastases. Ann Oncol,2004,15(suppl 4):iv103-iv106.
[2] Israel O, Kuten A. Early detection of cancer recurrence:18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med, 2007, 48(Suppl):28S-35S.
[3] Schroder FH, Roobol MJ. Words of wisdom. Re:prostate-specific antigen(PSA)and PSA velocity for prostate cancer detection in men aged <50 years. Eur Urol, 2007, 52(3):922.
[4] Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer:the utility of positron emission tomography (PET). Eur J Cancer, 2001, 37(7):862-869.
[5] Hung GU, Shiau YC, Tsai SC, et al. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res, 2001, 21(2B):1375-1378.
[6] Kalff V. Hicks RJ, Ware RE, et al. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer:a prospective study. J Nucl Med, 2002, 43(4):492-499.
[7] Krestin GP, Steinbrich W, Friedmann G. Recurrent rectal cancer:diagnosis with MR imaging versus CT. Radiology, 1988, 168(2):307-311.
[8] Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med, 2000, 41(7):1177-1189.
[9] Torizuka T, Nobezawa S, Kanno T, et al, Ovarian cancer recurrence:role for whole-body positron emission tomography using 2-[fluorine18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging, 2002, 29(6):797-803.
[10] Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2eoxyglucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol, 2001, 83(2):310-315.
[11] Kostakoglu L, Agress H, Goldsmith J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics, 2003, 23(2):315-340.
[12] Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer:additional value for diagnostic imaging and patient management. J Nucl Med, 2003, 44(8):1200-1209.
[13] Isasi CR, Moadel R, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat, 2005, 90(2):105-112.
[14] Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer, 2006, 107(11):2545-2551.
[15] Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med, 2002, 46(2):113-121.
[16] Aide N, Huchet V, Switsers O, et al. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun, 2007, 28(4):267-272.
[17] Simcock B, Neesham D, Quinn M, et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol, 2006, 103(1):271-276.
[18] Murakami M, Miyamoto T, Iida T, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer, 2006, 16(Suppl 1):99-107.
[19] Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol, 2005, 97(1):183-191.
[20] Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys, 2004, 55(4):907-913.
[21] Lai CH, Huang KG, See LC, et al. Restaging of recurrent cervical cancer with dual-phase[18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer, 2004, 100(3):544-552.
[22] Lin CT, Yen TC, Chang TC, et al. Role of[18F] fluoro-2-deoxy-Dglucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol Cancer, 2006, 16(6):1994-2003.
[23] Kim JH, Czernin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer, J Nucl Med, 2005, 46(4):587-595.
[24] Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging, 2006, 33(7):779-784.
[25] Cohade C, Osman M, Leal J, et al. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med, 2003, 44(11):1797-1803.
[26] Shen YY, Liang JA, Chen YK, et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA)in Taiwan. Hepatogastroenterology, 2006, 53(69):348-350.
[27] Pracchia LF, Chaves AR, Cerci JJ, et al. Metabolic test with fluorine18-fluorodeoxyglucose in staging and cetetion fo residual tumor or recurrence in Hodgkin lymphoma. Clinics, 2007, 62(2):121-126.
[28] Panizo C, Perez-Salazar M, Bendandi M, et al. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease medlastinal masses. Leuk Lymphoma, 2004, 45(9):1829-1833.
[29] Guay C, Lepine M, Verreault J, et al. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evalution. J Nucl Med, 2003, 44(8):1225-1231.